Vaccine developments (original) (raw)

• Levine, M.M., Woodrow, G.C., Kaper, J.B. & Cobon, G.S. New generation vaccines. Second edn (Marcel Dekker, Inc., New York, 1997).
  Google Scholar
• Fenner, F., Henderson, D.A., Arita, L., Jezek, Z. & Ladnyi, I.D. Smallpox and its eradication (World Health Organization, Geneva, 1988).
  Google Scholar
• Jenner, E. An inquiry into the causes and effects of the variolae vaccinae, a disease discovered in some of the western counties of England, particularly Gloucestershire, and known by the name of the cow pox. London, 1798, in Classics of Medicine and Surgery (ed. Camac, C.N.B.) 213–40 (Dover, New York, 1959).
  Google Scholar
• Pasture, L., Chamberland, C.-E. & Roux, E. Sur la vaccination charbonneuse. CR Acad Sci,Paris 92, 1378–1383 (1881).
  Google Scholar
• Pasteur, L. Une statistique au sujet de la vaccination préventive contre le charbon, portant sur quatre-vingt-cinq-mille animaux. CR Acad Sci, Paris 95, 1250–1252 (1882).
  Google Scholar
• Calmette, A. La vaccination preventive contre la tuberculose par le BCG (Masson, Paris, 1927).
• Maassab, H.F. & DeBorde, D.C. Development and characterization of cold-adapted viruses for use as live virus vaccines. Vaccine 3, 355–371 (1985).
  Article CAS Google Scholar
• Daniel, M.D., Kirchhoff, F., Czajak, S.C., Sehgal, P.K. & Desrosiers, R.C. Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258, 1938–1941 (1992).
  Article CAS Google Scholar
• Almond, N. . et al. Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells. Lancet 345, 1342–1344 (1995).
  Article CAS Google Scholar
• Lohman, B.L. et al. A partially attenuated simia duces host immunity that correlates with resist n immunodeficiency virus in-nce to pathogenic virus challenge. J. Virol. 68, 7021–7091 (1994).
  CAS PubMed PubMed Central Google Scholar
• Ruprecht, R.M. et al. “Attenuated” simian immunodeficiency virus in macaque neonates. AIDS Res. Hum Retroviruses 12, 459–460 (1996).
  Article CAS Google Scholar
• Baba, T.W. et al. Pathogenicity of live, attenuated SIV after mucosal infection of neonatal macaques. Science 267, 1820–1825 (1995).
  Article CAS Google Scholar
• Treanor, J.J. et al. Evaluation of the protective efficacy of a serotype 1 bovine-human rotavirus reassortant vaccine in infants. Pediatr. Infect. Dis. J. 14, 301–307 (1995).
  Article CAS Google Scholar
• Rennels, M.B. et al. Safety and efficacy of high-dose rhesus-human reassortant rotavirus vaccines—report of the National Multicenter Trial. United States Rotavirus Vaccine Efficacy Croup. Pediatrics 97, 7–13 (1996).
  CAS Google Scholar
• Smith, G.L. & Moss, B. Infectious poxvirus vectors have capacity for at least 25,000 base pairs of foreign DNA. Gene 25, 21–28 (1983).
  Article CAS Google Scholar
• Jones, L., Ristow, S., Yilma, T. & Moss, B. Accidental human vaccination with vaccinia virus expressing nucleoprotein gene [letter]. Nature 319, 543 (1986).
  Article CAS Google Scholar
• Cooney, E.L. et al. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein. Lancet 337, 567–572 (1991).
  Article CAS Google Scholar
• Rooney, J.F., Wohlenberg, C., Cremer, K.J., Moss, B. & Notkins, A.L. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination. J. Virol. 62, 1530–1534 (1988).
  CAS PubMed PubMed Central Google Scholar
• Kundig, T.M., Kalberer, C.P., Hengartner, H. & Zinkernagel, R.M. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination. Vaccine 11, 1154–1158 (1993).
  Article CAS Google Scholar
• Hanke, T. et al. Enhancement of MHC class l-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16, 439 (1998).
  Article CAS Google Scholar
• Fries, L.F. et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 14, 428–434 (1996).
  Article CAS Google Scholar
• Frolov, I. et al. Alphavirus-based expression vectors: Strategies and applications. Proc. Natl. Acad. Sci. USA 93, 11371–11377 (1996).
  Article CAS Google Scholar
• Xiong, C. et al. Sindbis virus: an efficient, broad host range vector for gene expression in animal cells. Science 243, 1188–1191 (1989).
  Article CAS Google Scholar
• Davis, N.L., Brown, K.W. & Johnston, R.E. A viral vaccine vector that expresses foreign genes in lymph nodes and protects against mucosal challenge. J. Virol. 70, 3781–3787 (1996).
  CAS PubMed PubMed Central Google Scholar
• Caley, I.J. et al. Humoral, mucosal, and cellular immunity in response to a human immunodeficiency virus type 1 immunogen expressed by a Venezuelan equine encephalitis virus vaccine vector. J. Virol. 71, 3031–3038 (1997).
  CAS PubMed PubMed Central Google Scholar
• Sizemore, D.R., Branstrom, A.A. & Sadoff, J.C. Attenuated Shigella as a DNA delivery vehicle for DNA-mediated immunization. Science 270, 299–302 (1995).
  Article CAS Google Scholar
• Darji, A. et al. Oral somatic transgene vaccination using attenuated S. typhimurium. Cell. 91, 765–775 (1997).
  Article CAS Google Scholar
• Goossens, P.L., Milon, G., Cossart, P. & Saron, M.F. Attenuated Listeria mono-cytogenes as a live vector for induction of CD8+ T cells in vivo: a study with the nucleoprotein of the lymphocytic choriomeningitis virus. Int. Immunol. 7, 797–805 (1995).
  Article CAS Google Scholar
• Dietrich, G. et al. Delivery of antigen-encoding plasmid DNA into the cytosol of macrophages by attenuated suicide Listeria monocytogenes. Nature Biotechnol. 16, 181–185 (1998).
  Article CAS Google Scholar
• Hoth, D.F., Bolognesi, D.P., Corey, L. & Vermund, S.H. HIV vaccine development: a progress report. Ann Intern. Med. 8, 603–611 (1994).
  Article Google Scholar
• Clements-Mann, M.L. et al. HIV-1 immune responses induced by canarypox (ALVAC) gp-160 MN, SF2 rgpi 20, or both vaccines in seronegative adults. J. of Infect. Dis. (In press).
• Graham, B.S. & Wright, P.F. Candidate AIDS vaccines. N. Engl. J. Med. 333, 1331–1339 (1995).
  Article CAS Google Scholar
• Murphy, T.V. et al. Declining incidence of Haemophilus influenzae type b disease since introduction of vaccination. JAMA 269, 246–248 (1993).
  Article CAS Google Scholar
• Hofmann, J. et al. The prevalence of drug-resistant Streptococcus pneumoniae in Atlanta. N. Engl. J. Med. 333, 481–486 (1995).
  Article CAS Google Scholar
• Flarend, R.E. et al. In vivo absorption of aluminium-containing vaccine adjuvants using 26AI. Vaccine 15, 1314–1318 (1997).
  Article CAS Google Scholar
• Gupta, R.K. & Siber, G.R. Adjuvants for human vaccines—current status, problems and future prospects. Vaccine 13, 1263–1276 (1995).
  Article CAS Google Scholar
• Cox, J.C. & Coulter, A.R. Adjuvants—a classification and review of their modes of action. Vaccine 15, 248–256 (1997)
  Article CAS Google Scholar
• Gupta, R.K., Chang, A.C., Griffin, P., Rivera, R. & Siber, G.R. In vivo distribution of radioactivity in mice after injection of biodegradable polymer microspheres containing 14C-labeled tetanus toxoid. Vaccine 14, 1412–1416 (1996).
  Article CAS Google Scholar
• Anderson, J.M. & Shive, M.S. Biodegradation and biocompatibility of PLA and PLGA microspheres. Advanced Drug Delivery Reviews 28, 5–24 (1997).
  Article CAS Google Scholar
• Tamura, S. et al. Synergistic action of cholera toxin B subunit (and Escherichia coli heat-labile toxin B subunit) and a trace amount of cholera whole toxin as an adjuvant for nasal influenza vaccine. Vaccine 12, 419–426 (1994).
  Article CAS Google Scholar
• Glenn, G.M., Rao, M., Matyas, G.R. & Alving, C.R. Skin immunization made possible by cholera toxin. Nature 391, 851 (1998).
  Article CAS Google Scholar
• Robbins, J.B., Schneerson, R. & Szu, S.C. Hypothesis: how licensed vaccines confer protective immunity. Adv. Exp. Med. Biol. 397, 169–182 (1996).
  Article CAS Google Scholar
• Haq, T.A., Mason, H.S., Clements, J.D. & Arntzen, C.J. Oral immunization with a recombinant bacterial antigen produced in transgenic plants. Science 268, 714–716 (1995).
  Article CAS Google Scholar
• Mason, H.S. et al. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc. Natl. Acad. Sci. USA 93, 5335–5340 (1996).
  Article CAS Google Scholar
• Arakawa, T., Chong, D.K.X. & Langridge, W.H.R. Efficacy of a food plant-based oral cholera toxin B subunit vaccine. Nature Biotechnol. 16, 292–298 (1998).
  Article CAS Google Scholar
• Donnelly, J.J., Ulmer, J.B., Shiver, J.W. & Liu, M.A. DNA vaccines. Annu. Rev. Immunol. 15, 617–648 (1997).
  Article CAS Google Scholar
• Martinon, F. et al. Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA. Eur. J. Immunol. 23, 1719–1722 (1993).
  Article CAS Google Scholar
• Ward, G., Reider, E. & Mason, P.W. Plasmid DNA encoding replicating foot and mouth disease virus genomes induces antiviral immune responses in swine, journal of Virology 71, 7442–7447 (1997).
  CAS PubMed PubMed Central Google Scholar
• Hariharan, M.J. et al. DNA immunization against herpes simplex virus: enhanced efficacy using a sindbis virus-based vector. J. Virol. 72, 950–958 (1998).
  CAS PubMed PubMed Central Google Scholar
• Macatonia, S.E., Patterson, S. & Knight, S.C. Primary proliferative and cytotoxic T-cell responses to HIV induced in vitro by human dendritic cells. Immunology 74, 399–406 (1991).
  CAS PubMed PubMed Central Google Scholar
• Nestle, F.O. et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 4, 328–332 (1998).
  Article CAS Google Scholar
• Fleischmann, R.D. et al. Whole-genome random sequencing and assembly of Haemophilus influenzae Rd. Science 269, 496–512 (1995).
  Article CAS Google Scholar
• Orme, I.M. Prospects for new vaccines against tuberculosis. Trends In Microbiology 3, 401–404 (1995).
  Article CAS Google Scholar